Tag Archives: FibroGen

Akebia crashes on vadadustat flop in larger anemia indication. Will AZ, FibroGen own the market?

What was previously expected to be a three-way battle in the novel HIF-PHI renal anemia drug class now has one man down. Akebia Therapeutics has posted a surprise trial flop, which one analyst said could hand the rival FibroGen-AstraZeneca team an early monopoly of the market. On Thursday, Akebia said its Otsuka-partnered vadadustat was linked to… Read More »

FibroGen founder Thomas Neff dies suddenly as drug he championed racks up milestones

After founding FibroGen in 1993 and leading the company for 26 years, chairman and CEO Thomas B. Neff passed away over the weekend unexpectedly. His death comes as FibroGen nears the critical U.S. and European filings for its Astellas- and AstraZeneca-partnered oral anemia med roxadustat, which recently won its second approval in China.  Thomas Neff With Neff’s… Read More »